Last reviewed · How we verify
Catecholamines
Catecholamines is a Small molecule drug developed by University of Regensburg. It is currently in Phase 1 development. Also known as: Norephinephrine.
Catecholamines are a class of monoamine neurotransmitters, specifically organic compounds with a catechol and a side-chain amine. They are studied in various clinical trials for conditions such as adverse effects, sepsis, critical illness, postural tachycardia syndrome, and vasovagal syncope, often in relation to interventions involving norepinephrine and phenylephrine.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Catecholamines |
|---|---|
| Also known as | Norephinephrine |
| Sponsor | University of Regensburg |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Laboratory Evaluation of Chronic Autonomic Failure
- Effects of Local Ketamine in Orthognathic Procedures (NA)
- Diagnosis of Pheochromocytoma (PHASE1)
- Cortical Electrophysiology of Response Inhibition in Parkinson's Disease (PHASE4)
- Comparing Two Different Norepinephrine Infusion Rates for Prophylaxis Against Spinal-induced Hypotension in Elderly (NA)
- Effect of Adding a Low-Dose Epinephrine Bolus Prior to Infusion on Maternal Hemodynamic Stability During Cesarean Section (PHASE3)
- The Efficiency of Periarticular Multimodal Drug Injection in Pain Management Following Primary Unilateral TKA (NA)
- Vasopressor Impact on Brain Circulation, Organ Blood Flow and Tissue Oxygenation During Anesthesia (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Catecholamines CI brief — competitive landscape report
- Catecholamines updates RSS · CI watch RSS
- University of Regensburg portfolio CI
Frequently asked questions about Catecholamines
What is Catecholamines?
Who makes Catecholamines?
Is Catecholamines also known as anything else?
What development phase is Catecholamines in?
Related
- Manufacturer: University of Regensburg — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Norephinephrine